Company profile
PepGen Inc.
NASDAQ:PEPGBiotechnology: Pharmaceutical Preparations
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06667453 | phase2 | recruiting | 2024-12-10 | 2027-03-01 | PepGen Inc | A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 |
| NCT06079736 | phase2 | terminated | 2024-01-03 | 2025-08-28 | PepGen Inc | A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable To Exon 51-Skipping Treatment |
| NCT06833931 | phase2 | withdrawn | 2024-12-17 | 2025-05-28 | PepGen Inc | A Study of PGN-EDO51 or Placebo in People With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment |
| NCT07220603 | phase2 | recruiting | 2025-12-23 | 2029-01-01 | PepGen Inc | An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE) |
| NCT06204809 | phase1 | completed | 2023-12-12 | 2025-10-28 | PepGen Inc | Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1 |
FDA applications (0)
No records yet.